Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg1/9 cls
Cempra Inc. (NASDAQ:CEMP)NeedhamAlan CarrPrice targetBuy13%$25.78
Carr raised his target to $42 from $28 after oral solithromycin (CEM-101) met the primary endpoint in the Phase III Solitaire-Oral trial to treat community-acquired bacterial pneumonia (CABP). Carr estimates over $2B

Read the full 458 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE